Skip to main content
Premium Trial:

Request an Annual Quote

Ferrer to be Agendia's Latin America Distributor

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia said today that it has hired Ferrer inCode to distribute its MammaPrint breast cancer diagnostic test in Latin America.

The MammaPrint test is used to identify patients who are at high risk of early metastasis and who are likely to develop metastases within five years after surgery.

Ferrer inCode is a subsidiary of Spain's Grupo Ferrer Internacional that is focused on personalized medicine, genomics, proteomics, and other related technologies.

"Ferrer has a strong presence in most of the Latin American key markets, most notably in rapidly emerging countries such as Brazil and Argentina, and has made great strides towards reimbursement in a number of Latin American countries," Bas van der Baan, Agendia's VP of commercial operation Europe/ROW, said in a statement.